Thomas Lodise

Thomas Lodise

Education

  • PhD, Epidemiology, University at Albany
  • PharmD, Temple University School of Pharmacy

Courses Taught at ACPHS

  • Drug Information (study design and statistics)
  • Epidemiology I
  • Epidemiology II

Research Interests

  • Integrating his dual interests in scholarship and patient care, Dr. Lodise’s overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure-response relationships in patients with invasive bacterial infections. His research encompasses three interrelated domains: pharmacokinetics (PK)/pharmacodynamics (PD), epidemiology, and outcomes.
  • His specific research objectives are 4-fold: develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs. In short, his research works to define the “right antibiotic at the right dose for the right patient.”
  • Research cannot improve patient care unless the knowledge is transferable. To this end, he employs cutting-edge mathematical modeling techniques to identify patient- and treatment-related factors that promote optimal patient-centered outcomes.  Advanced pharmacoepidemiologic and comparative effectiveness methodologies are also leveraged to determine optimal empiric and targeted treatment strategies for patients with antibiotic resistant infections. In addition, he uses state-of-the-art PK/PD methods to design antibiotic dosing schemes that optimize efficacy and minimize drug toxicity for implementation into clinical practice. He is particularly interested in identifying optimal dosing schemes for patient populations that are typically underrepresented in Phase III clinical.
  • To date, he has published over 100 peer-reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Lancet Infectious Diseases, Chest, and Journal of Antimicrobial Chemotherapy. He has also secured over $1.5 million in grant funding from various sources.

Learn More About Dr. Lodise

  • New York Chapter of American College of Clinical Pharmacy Researcher of the Year (2015)
  • Society of Infectious Diseases Pharmacists (SIDP) Impact Paper of the Year (2015)
  • Researcher of the Year (First Inaugural) Albany College of Pharmacy and Health Sciences (2013)
  • Clinical Infectious Diseases Award for Outstanding Journal Article Review (2010)
  • Society of Infectious Diseases Pharmacists (SIDP) Impact Paper of the Year (2010)
  • Clinical Infectious Diseases Award for Outstanding Journal Article Review (2009)
  • Society of Infectious Diseases Pharmacists (SIDP) Young Investigator of the Year (2008)
  • Clinical Infectious Diseases Award for Outstanding Journal Article Review (2007)
  • American College of Clinical Pharmacy (ACCP) Infectious Diseases PRN and the ACCP Research Institute Infectious Diseases PRN Mini-sabbatical Mentor (2007)
  • New York Chapter of American College of Clinical Pharmacy Researcher of the Year (2006)
  • American College of Clinical Pharmacy (ACCP) Infectious Diseases PRN and the ACCP Research Institute Infectious Diseases PRN Mini-sabbatical Mentor (2005)

Dr. Lodise is a Clinical Pharmacist at the Stratton VA Medical Center in Albany, NY.

Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Lodise T. Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections. The American Journal of the Medical Sciences 2019 Feb;357(2):103-110. doi: 10.1016/j.amjms.2018.11.009. Epub 2018 Nov 22. PubMed PMID: 30665490.

Tartof SY, Kuntz JL, Chen LH, Wei R, Puzniak L, Tian Y, Im TM, Takhar HS, Merchant S, Lodise T. Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection. JAMA Network Open 2018 Oct 5;1(6):e183927. doi: 10.1001/jamanetworkopen.2018.3927. PubMed PMID: 30646267; PubMed Central PMCID: PMC6324445.

Hardalo C, Lodise TP, De Anda C. Myelosuppression with Oxazolidinones: Are There Differences? Antimicrobial Agents and Chemotherapy 2018 Dec 21;63(1). pii: e01833-18. doi: 10.1128/AAC.01833-18. Print 2019 Jan. PubMed PMID: 30578404.

Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ. Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State. Open Forum Infectious Diseases 2018 Nov 16;5(11):ofy297. doi: 10.1093/ofid/ofy297. eCollection 2018 Nov. PubMed PMID: 30539040; PubMed Central PMCID: PMC6284462.

Lodise TP, Zhao Q, Fahrbach K, Gillard PJ, Martin A. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? BMC Infect Diseases 2018 Dec 5;18(1):625. doi: 10.1186/s12879-018-3524-8. PubMed PMID: 30518337; PubMed Central PMCID: PMC6280436.

  • LaPensee K, Lodise T. Cost-savings Analysis with Use of Omadacycline Among Hospitalized Community-Acquired Pneumonia Patients At Risk of Clostridium difficile Infection Being Treated with Moxifloxacin: Budget Impact Model Findings. ASHP Midyear Clinical Meeting, Anaheim CA, December 2-6, 2018. Poster #4-049. Presenter: LaPensee.
  • LaPensee K, Lodise T. Cost-saving Opportunities Among Hospitalized Community-Acquired Pneumonia Patients Treated with Omadacycline, an Aminomethylcycline Antibiotic with IV and Oral Formulations, Compared to Ceftriaxone and Macrolide Therapy. ASHP Midyear Clinical Meeting, Anaheim CA, December 2-6, 2018. Poster #4-048. Presenter: LaPensee.
  • Lodise T, LaPensee K. Hospital Admission Patterns in Adult Patients with Community-acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract #1462. Presenter: Lodise.
  • Patel N, Clark J, Stornelli N, Belfiore G, Lodise TP. Comparative Evaluation of Adverse Tendon Events between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract #1463. Presenter: Patel.
  • Puzniak L, Fu R, Gundrum J, Lodise TP. Real World Evaluation of Patient Characteristics and Outcomes of Patients Treated with Ceftolozane/Tazobactam across 253 US hospitals. IDweek2018, San Francisco CA, October 3-7, 2018. Abstract # 2414. Presenter: Lodise.

Role: Principal Investigator
Project Title: A Phase 1 Study In Healthy Young Adults To Evaluate The Safety And Pharmacokinetics Of AVYCAZ® In Combination With Aztreonam (COMBINE)
Grantor: Sub-award through Duke University; Primary sponsor: National Institute of Allergy and Infectious Diseases
Amount at ACPHS: $90,000
Grant Number: 1UM1AI104681-06
Term: 11/01/2018 – 12/31/2018

Role: Co-Investigator (PI: Richard Wunderlink, MD)
Project Title: An Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (Acumin)
Grantor: Sub-award through Duke University; Primary sponsor: National Institute of Allergy and Infectious Diseases
Grant Number: 1UM1AI104681-01
Amount at ACPHS: $48,000
Term: 11/01/18 – 12/31/18

Role: Chair (PI: Vance Fowler, MD)
Project Title: PK ARLG Steering Committee Chair
Grantor: Sub-award through Duke University; Primary sponsor: National Institute of Allergy and Infectious Diseases
Grant Number: 1UM1AI104681-01
Amount at ACPHS: $342,000
Term: 1/01/18- 12/31/18